Breast Cancer | Matthew Goetz, MD - a podcast by Dr Neil Love
from 2019-10-28T19:20:01
::
::
Breast Cancer Update, Issue 3, 2019 — Part 1: Our interview with Dr Goetz highlights the following topics as well as cases from his practice:
- Case: A woman in her mid-30s with de novo ER-positive, HER2-negative metastatic breast cancer (mBC) achieves a complete clinical response to palbociclib, letrozole and ovarian suppression (00:00)
- Importance of providing support to patients and their families coping with a diagnosis of mBC (01:15)
- Therapeutic options for patients with de novo ER-positive, HER2-negative mBC (03:45)
- Activity and tolerability of gonadotropin-releasing hormone agonists (05:35)
- Selection of patients for treatment with CDK4/6 inhibitors in combination with endocrine therapy (09:07)
- Mechanism of action of CDK4/6 inhibitors (12:13)
- Role of everolimus and alpelisib in the management of ER-positive mBC (14:30)
- Implications of ESR1 mutations for the management of ER-positive mBC; use of selective estrogen receptor degraders (SERDs) (16:15)
- Activity of the selective estrogen receptor modulators endoxifen and lasofoxifene for mBC with ESR1 mutation (19:48)
- Tolerability profiles of the CDK4/6 inhibitors palbociclib, ribociclib and abemaciclib; dose reduction to mitigate side effects (21:21)
- CNS penetration of abemaciclib; management of abemaciclib-associated diarrhea (25:26)
- Effects of site and extent of metastases on outcomes with CDK4/6 inhibitors (27:02)
- Efficacy of CDK4/6 inhibitors in combination with endocrine therapy for ER-positive mBC (29:29)
- Survival outcomes with CDK4/6 inhibitors and endocrine therapy for ER-positive mBC (31:28)
- Response to palbociclib and endocrine therapy in patients with ER-positive mBC (34:17)
- Selection of therapy for patients with locally advanced ER-positive, HER2-negative breast cancer (36:41)
- Therapeutic approach for patients who experience disease progression on a CDK4/6 inhibitor (39:33)
- Activity of alpelisib for ER-positive advanced breast cancer with a PIK3CA mutation (47:02)
- Side-effect profile of alpelisib (49:41)
- Case: A woman in her late 60s with high-grade, ER-positive, HER2-negative breast cancer and a 21-gene assay Recurrence Score (RS) of 52 receives adjuvant chemotherapy (52:54)
- Role of bone-modifying agents for patients with ER-positive breast cancer and bone metastases (58:04)
- Ongoing investigations of CDK4/6 inhibitors in the adjuvant setting (59:40)
- Effects of CDK4/6 inhibitors on immunity; potential for combination with immune checkpoint inhibitors (1:01:14)
- TAILORx trial: Adjuvant chemotherapy guided by a 21-gene expression assay for women with ER-positive, HER2-negative, node-negative breast cancer (1:06:19)
- Impact of clinical risk on prognosis and prediction of chemotherapy benefit by age and RS in the TAILORx study for patients with early breast cancer (1:07:46)
- Perspective on the use of gene expression assays to determine risk of recurrence and guide adjuvant decision-making (1:14:30)
- Cancer cell dormancy and risk of late recurrence (1:16:47)
CME information and select publications
Further episodes of Research To Practice | Oncology Videos
Further podcasts by Dr Neil Love
Website of Dr Neil Love